<DOC>
	<DOCNO>NCT01531205</DOCNO>
	<brief_summary>The aim study test whether add chemotherapy/cabazitaxel hormonal/androgen deprivation therapy surgical removal prostate would improve outcome salvage surgery locally recurrent prostate cancer initial primary radiation therapy .</brief_summary>
	<brief_title>Neoadjuvant Chemohormonal Therapy Followed Salvage Surgery High Risk PSA</brief_title>
	<detailed_description>In study , participant receive cabazitaxel chemotherapy , approve second line chemotherapy treat metastatic prostate cancer . Standard hormone androgen ablation therapy also use part chemohormonal therapy prior surgery .</detailed_description>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy must 10 year Peripheral neuropathy : must &lt; /= grade 1 A minimum PSA 1 ng/ml androgen deprivation therapy Patients must one follow criterion eligible : PSA recurrence double time le 9 month ( calculate least 3 PSA value obtain least 4 week apart ) Prostatic biopsy Gleason Grade &gt; /= 8 time initial biopsy prior radiation therapy determine either outside pathology report review slide institutional pathologist ( ) Clinical stage &gt; /= T3 ( define evidence extracapsular seminal vesicle extension digital rectal examination transrectal ultrasonography ) either time initial diagnosis follow radiotherapy Prior radiation therapy type include external beam radiotherapy , brachytherapy , high dose radiotherapy , proton therapy Positive prostate biopsy document local recurrence follow radiation therapy Prior androgen deprivation therapy total duration 36 month allowable . Patients LHRH analog therapy continue therapy provide patient castration resistant prostate cancer ( rise PSA presence castrate level serum testosterone , ie &lt; 50 ng/dl ) . Androgen deprivation therapy LHRH analog discontinue 4 week prior study enrollment . All prostatic carcinoma variant except small cell carcinoma prostate allow . Patients must evidence metastatic disease bone scan abdominal/pelvic CT MRI perform within 30 day study enrollment . All patient must regard acceptable anesthetic risk salvage surgery ( salvage radical prostatectomy , salvage cystoprostatectomy , salvage total pelvic exenteration ) confirm intention undergo salvage surgery end neoadjuvant chemohormonal therapy . Patients must adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500/mm^3 platelet count &gt; 100,000/mm^3 ; adequate hepatic function define total bilirubin &lt; 1.5 mg/dl aspartic transaminase/alanine transaminase ( AST/ALT ) &lt; 1.5 X upper limit normal ( ULN ) ; adequate renal function define serum creatinine clearance &gt; 60 ml/min ( measure calculate ) . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients must sign informed consent indicate aware investigational nature study , keep policy institution . All patient must evaluate Department Genitourinary Oncology prior sign inform consent . Patients small cell histology Patients clinical , radiological , pathological evidence bone , lymph node visceral metastasis ( liver lung metastasis ) Castration resistant prostate cancer define rise PSA profile set castrate level testosterone ( serum testosterone &lt; 50 ng/dl ) Prior chemotherapy Patients severe uncontrolled intercurrent infection Patients New York Heart Association ( NYHA ) Class III/IV congestive heart failure , unstable angina history myocardial infarction within last 6 month Contraindications corticosteroid Uncontrolled severe hypertension , persistently uncontrolled diabetes mellitus , oxygen dependent lung disease , chronic liver disease HIV infection Second malignancy ( exclude nonmelanoma skin cancer ) unless diseasefree 3 year Overt psychosis , mental disability otherwise incompetent give inform consent Patients history severe hypersensitivity reaction CabazitaxelÂ® drug formulate polysorbate 80</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent</keyword>
	<keyword>high risk</keyword>
</DOC>